BiotechTube

Mirabegron + Solifenacin succinate

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Urologic Diseases

Conditions

Urologic Diseases, Urinary Bladder, Overactive, Urinary Bladder Diseases

Trial Timeline

Jun 12, 2012 → Apr 24, 2013

NCT ID
NCT01638000

About Mirabegron + Solifenacin succinate

Mirabegron + Solifenacin succinate is a phase 3 stage product being developed by Astellas Pharma for Urologic Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT01638000. Target conditions include Urologic Diseases, Urinary Bladder, Overactive, Urinary Bladder Diseases.

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01638000Phase 3Completed

Competing Products

16 competing products in Urologic Diseases

See all competitors
ProductCompanyStageHype Score
pemetrexed + cisplatinEli LillyPhase 1/2
32
Mirabegron + Solifenacin succinate + PlaceboAstellas PharmaPhase 2
35
GemcitabineEli LillyPhase 2
35
pemetrexedEli LillyPhase 2
35
ALIMTA + gemcitabineEli LillyPhase 2
35
BBI503Sumitomo PharmaPhase 2
27
Pembrolizumab Injection [Keytruda]MerckPhase 2
42
Carboplatin/Paclitaxel + PembrolizumabMerckPhase 2
42
zoledronic acidNovartisPhase 2
27
mycophenolate mofetilRochePhase 1
29
Cetuximab + PaclitaxelBristol Myers SquibbPhase 2
35
Nivolumab + RelatlimabBristol Myers SquibbPhase 2
42
CBT101 + PlaceboBrain BiotechPhase 1
26
OGX-427 600 mg + OGX-427 1000 mg + Placebo + Gemcitabine + Cisplatin + CarboplatinAchieve Life SciencesPhase 2
25
S-8184 Paclitaxel Injectable Emulsion + Experimental Arm: TOCOSOL PaclitaxelAchieve Life SciencesPhase 2
25
Stem CellBrain BiotechPhase 1
11